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Abstract
Purpose The FANCM c.5101C[T nonsense mutation was
previously found to associate with breast cancer in the
Finnish population, especially among triple-negative cases.
Here, we studied the prevalence of three other FANCM
variants: c.5791C[T, which has been reported to predis-
pose to familial breast cancer, and the c.4025_4026delCT
and c.5293dupA variants recently identified in Finnish
cancer patients.
Methods We genotyped the FANCM c.5791C[T mutation
in 4806 invasive breast cancer patients, including BRCA1/2
mutation negative familial cases and unselected cases, and
in 2734 healthy population controls from four different
geographical areas of Finland. The association of the
mutation with breast cancer risk among patient subgroups
was statistically evaluated. We further analyzed the com-
bined risk associated with c.5101C[T and c.5791C[T
mutations. We also genotyped 526 unselected ovarian
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cancer patients for the c.5791C[T mutation and 862
familial breast cancer patients for the c.4025_4026delCT
and c.5293dupA variants.
Results The frequency of the FANCM c.5791C[T muta-
tion was higher among breast cancer cases than in controls
(OR 1.94, 95% CI 0.87–4.32, P = 0.11), with a statisti-
cally significant association with triple-negative breast
cancer (OR 5.14, 95% CI 1.65–16.0, P = 0.005). The
combined analysis for c.5101C[T and c.5791C[T carriers
confirmed a strong association with breast cancer (OR 1.86,
95% CI 1.32–2.49, P = 0.0002), especially among the
triple-negative patients (OR 3.08, 95% CI 1.77–5.35,
P = 0.00007). For the other variants, only one additional
c.4025_4026delCT carrier and no c.5293dupA carriers
were observed.
Conclusions These results support the role of FANCM as a
breast cancer susceptibility gene, particularly for triple-
negative breast cancer.
Keywords FANCM  Breast cancer  Triple-negative
breast cancer  Familial breast cancer  DNA repair
Abbreviations
FA Fanconi anemia
ICL Interstrand crosslink
OR Odds ratio
CI Confidence interval
TNBC Triple-negative breast cancer
ER Estrogen receptor
PR Progesterone receptor
HNPCC Hereditary non-polyposis colorectal cancer
Introduction
Fanconi Anemia complementation group M (FANCM) is a
multifunctional protein, interacting with several partners to
activate the Fanconi anemia (FA) repair pathway. The
pathway includes 19 associated proteins, which form
multiprotein complexes to repair damaged DNA, especially
stalled replication forks induced by interstrand cross-link-
ing (ICL) agents [1, 2]. FA itself is a rare, recessively
inherited genetic disorder causing congenital defects,
hematologic abnormalities, and cancer predisposition [1].
Despite the nomenclature, FANCM does not appear to
have a role in the FA disease, as the initial case, which led
to the FANCM association with FA, also carried biallelic
FANCA mutations. Furthermore, homozygous loss-of-
function mutations in FANCM have been identified in
individuals without any FA symptoms [3, 4]. However,
FANCM has an undeniable role in the FA pathway, as it
recruits other DNA damage response proteins to the sites of
DNA lesions [4]. Several FA genes (FANCD1/BRCA2,
FANCN/PALB2, FANCJ/BRIP1, FANCO/RAD51C, and
FANCS/BRCA1) [5–11] are high- or moderate-risk breast
or ovarian cancer susceptibility genes and previous studies
have connected also heterozygous FANCM mutations with
breast cancer predisposition [12–14].
We previously identified the FANCM c.5101C[T non-
sense mutation (rs147021911, p.Gln1701*) in exon 20 by
exome sequencing of germline DNA samples from 24
BRCA1/2-negative breast cancer patients and further geno-
typed it in a large series of Finnish breast cancer patients and
healthy population controls [12]. The mutation was found to
be associated with breast cancer with an odds ratio (OR) of
1.86 [95% confidence interval (CI) 1.26–2.75, P = 0.0018],
especially among triple-negative breast cancer [TNBC;
estrogen (ER) and progesterone (PR) receptor and HER2
negative] cases (OR 3.56, 95% CI 1.81–6.98, P = 0.0002).
According to the ExAC [15] database this mutation is more
common in Finland (carrier frequency*1.8%) than in other
European populations (carrier frequency*0.3%).
Another, yet more rare FANCM mutation, c.5791C[T
(rs144567652, p.Arg1931*) in exon 22, has been identified
with exome sequencing of breast cancer patients [16].
Further analysis of familial breast cancer cases and healthy
controls from several populations showed an association
between the mutation and familial breast cancer (OR 3.93,
95% CI 1.28–12.11, P = 0.017) [13]. A recent study in a
German population produced similar results, where the
loss-of-function mutations in the FANCM gene were
associated with both familial breast cancer and TNBC [14].
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c.5791C[T mutation has also been identified in two
colorectal cancer patients [17], and since FANCM is
functionally connected with the mismatch repair genes
MSH2/MSH6, it has previously been considered as a
potential candidate gene for hereditary non-polyposis col-
orectal cancer (HNPCC) [17, 18]. However, a combined
analysis of larger datasets did not reveal statistically sig-
nificant association between FANCM mutations and the
disease [19].
Here, we have investigated the association of the
FANCM c.5791C[T mutation with breast cancer risk in
familial and unselected breast cancer cases among 4806
invasive breast cancer patients and 2734 healthy popula-
tion controls from four different geographical areas of
Finland. We further evaluated the breast cancer risk by
subgroups of patients as well as ovarian cancer risk among
526 ovarian cancer patients. Also, the recently identified
c.4025_4026delCT (p.Ser1342*) and c.5293dupA
(p.Thr1765Asnfs*3) variants in the FANCM gene were
studied among 862 familial breast cancer patients from the
Helsinki area.
Moreover, to further study the risk associated with
truncating C-terminal FANCM mutations, we analyzed the
current results of the c.5791C[T mutation and risk esti-
mates of the c.5101C[T mutation, including the previously
published results from Helsinki and Tampere area [12] and
genotyping results from Oulu and Kuopio.
Methods
Subjects
Helsinki breast cancer series
The FANCM c.5791C[T mutation was genotyped in 2391
breast cancer cases (including unselected and familial
patients) and 1258 healthy female population controls from
the Helsinki area. Unselected breast cancer patient samples
were collected at the Helsinki University Central Hospital
in two phases. During 1997–1998 and 2000, 884 samples
were collected at the Department of Oncology. These
samples include 79% of all consecutive, newly diagnosed
breast cancer cases during the collection periods [20, 21].
During 2001–2004, 986 samples, including 87% of all
consecutive, newly diagnosed breast cancer cases were
collected at the Department of Surgery [21]. Only invasive
cases were included in this study.
The familial cases were collected at the Helsinki
University Central Hospital Departments of Oncology and
Clinical Genetics [22, 23]. Of these, 523 patients had a
strong family history with at least three breast or ovarian
cancers among first- or second-degree relatives (including
the proband), and 555 patients had at least one first-degree
relative affected with breast or ovarian cancer. All the
familial cohort patients with at least three breast or ovarian
cancers among first- or second-degree relatives were tested
negative for BRCA1/2 mutations and the patients with one
affected relative were tested negative for the Finnish
BRCA1/2 founder mutations as previously described
[24–26]. Eight hundred and sixty two familial cases were
genotyped for the c.4025_4026delCT and c.5293dupA
variants and 1078 familial cases were genotyped for the
FANCM c.5791C[T mutation.
The samples are genomic DNA isolated from peripheral
blood. The patient genealogies were confirmed from the
population registries or hospital records and cancer diag-
noses from the hospital records or the Finnish Cancer
Registry. Hormone receptor status was collected from
pathology reports as described earlier [27]. The 1258
genotyped population controls were healthy female blood
donors from the Helsinki area.
The unselected ovarian cancer cohort was collected at
the Helsinki University Central Hospital Department of
Obstetrics and Gynecology in 1998 as previously described
[28]. Blood samples were collected from invasive epithelial
ovarian carcinoma treated patients during routine follow-
up visits to the clinic. Additional samples were also col-
lected between 1998 and 2006. Out of the 526 independent
samples included in the analysis in this study, 408 were
genomic DNA isolated from blood and 118 samples were
tumor-DNA. Of the genomic samples, 171 were serous, 64
mucinous, and 43 endometrioid subtype. 129 samples were
other ovarian cancer subtypes, for one sample the subtype
is not known. Out of the tumor samples, 104 were serous
and two were other subtypes, 12 samples were of unknown
subtype.
Tampere breast cancer series
The unselected breast cancer patient sample set from the
Tampere area was collected at the Tampere University
Hospital as previously described [20, 22]. Additional 336
incident cases were collected in 1996–2004 at the Tam-
pere University Hospital. Two hundred and forty nine
cases had also familial background. Hormone receptor
status information was obtained from patient pathology
reports. Only invasive cases were included in this study.
All samples are genomic DNA isolated from peripheral
blood. The control cohort for the Tampere dataset consists
of 808 healthy female blood donors from the Tampere
area.
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Kuopio breast cancer series
430 patients with invasive breast cancer from the Kuopio
area were genotyped for the FANCM c.5791C[T and
c.5101C[T mutations. These patients belong to prospec-
tive population-based case–control study, The Kuopio
Breast Cancer Project (KBCP), which was conducted in
between 1990 and 1996. Samples were collected from
women entering the Kuopio University Hospital due to
breast symptoms and who were eventually diagnosed as
having breast cancer. All samples are genomic DNA iso-
lated from peripheral blood. Information about hormonal
receptor status was obtained from hospital registries
[29, 30]. The control cohort consists of 158 healthy blood
donors from the Kuopio area.
Oulu breast cancer series
The FANCM c.5791C[T and c.5101C[T mutations were
screened among 1323 breast cancer cases (1147 unselected,
153 familial, and 56 young breast cancer patients) and 510
healthy female controls from the Oulu area. The unselected
breast cancer samples were collected from patients oper-
ated at the Oulu University Hospital during 2000–2014,
and they were unselected for age at disease onset and a
family history of cancer. Only invasive cases were included
in this study. The familial breast cancer cases were affected
index individuals of Northern Finnish breast or breast and
ovarian cancer families, and the young cohort consisted of
breast cancer patients unselected for family history of
cancer but with early disease onset (B40 years), which
suggests a plausible hereditary predisposition regardless of
the family history [31–33]. Only BRCA1/2 mutation neg-
ative familial and young cases were included in this study.
Hormone receptor status was collected from pathology
reports as described earlier [34]. The control cohort con-
sisted of 510 healthy female blood donors from the Oulu
area. All samples were genomic DNA isolated from
peripheral blood.
This study was performed with informed consent from
all the patients and permission from the ethics committees
of University of Helsinki, Tampere University Hospital,
Oulu University Hospital, University of Eastern Finland,
and Kuopio University Hospital Board on Research Ethics.
Identification of the mutations
The FANCM c.5791C[T mutation has been found to
associate with familial breast cancer and TNBC [13, 14]. It
has also been reported in the Finnish population as an
enriched loss-of-function mutation [3] and identified in
gene panel sequencing of Finnish familial breast cancer
patients [35].
The c.4025_4026delCT variant was identified at Lund
University in one patient from 100 Finnish high-risk breast
cancer cases with panel sequencing, in which also two
carriers of the previously published c.5101C[T mutation
were identified. SureselectXT Custom 3-5.9 Mb library kit
(Agilent Technology) was used to capture DNA fragments
from the target genes. Sequencing was performed on the
Illumina HiSeq 2500 with 2 9 94 to 2 9 101 bp paired-
end reads.
The c.5293dupA variant was identified by exome
sequencing of genomic DNA samples from 44 Finnish
cancer patients with familial history of breast cancer.
Exome sequencing was executed at the Genome Quebec
Innovation Centre. To capture the exomic regions, Roche
Nimblegen SeqCap EZ Exome v3 kit was used. The
sequencing was performed on Illumina HiSeq 2000
sequencer with 100 bp paired-end reads.
The c.5101C[T mutation was identified by exome
sequencing as previously described [12].
Genotyping
Genotyping of the FANCM c.5791C[T mutation for the
Helsinki and Tampere sample sets was performed with
Sequenom MassARRAY system using iPLEX Gold assays
(Sequenom) at FIMM (University of Helsinki). Variants
c.4025_4026delCT and c.5293dupA were genotyped with
TaqMan real-time PCR. 7500 Fast Real Time system was
utilized by using TaqMan SNP Genotyping Custom assays
and TaqMan Genotyping MasterMix (Applied Biosys-
tems). Genotype calling was performed with 7500 Real-
Time PCR System and 7500 software (version 2.06,
Applied Biosystems). Genotyping for the FANCM
c.5101C[T mutation was performed as previously descri-
bed [12]. Positive controls were used in all analyses and all
mutations were confirmed with Sanger sequencing. It is to
be noted that one patient from the Helsinki dataset (counted
as one in the analysis) carries both c.5101C[T and
c.5791C[T mutations. Unfortunately, we were not able to
determine whether the mutations are in cis or in trans;
however, if they were in cis, this genotype would be
extremely rare.
FANCM c.5791C[T and c.5101C[T screening for Oulu
and Kuopio sample sets was performed using High Reso-
lution Melt analysis (CFX96, Bio-Rad) with Type-it HRM
reagents (Qiagen). Positive control DNA was included in
all analyses, and samples with positive-like or differing
melting curves were validated by Sanger sequencing
(ABI3130xl, Applied Biosystems).
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Statistical analyses
All statistical analyses were performed using R (version
3.02) statistical software (http://www.r-project.org) or IBM
SPSS Statistics for Windows, version 22.0. For the risk
analyses, two-sided P-values were calculated using Pear-
son´s v2-test or Fisher´s exact test if the expected number of
cell count was five or less. P\ 0.05 was considered sta-
tistically significant. Betas and standard errors of the dif-
ferent studies were combined in ‘‘rmeta’’-package to
examine heterogeneity between studies. In heterogeneity
analysis, P\ 0.10 was considered statistically significant.
In the combined analyses, all the datasets were pooled
and the odds ratios and P-values were estimated with
logistic regression model stratified by study. Separate
analysis were conducted for the subgroups defined by
histopathology and family history of the disease. In the
combined analysis including datasets for both FANCM
c.5791C[T and c.5101C[T mutations, patients with
genotyping results for both mutations were included in the
analysis.
Results
Genotyping of the FANCM c.5791C>T mutation
in the case–control sample sets
The FANCM c.5791C[T mutation was identified in alto-
gether 28 breast cancer patients and eight controls among
4806 breast cancer patients and 2734 population controls
from four different geographical areas of Finland (Helsinki,
Tampere, Kuopio, and Oulu). The population frequency
was highest in Northern and Eastern Finland (Oulu 0.6%
and Kuopio 0.6%) and lowest in Southern and South-
western Finland (Helsinki 0.2% and Tampere 0.1%).
Among the BRCA1/2-negative familial patients from Hel-
sinki and Oulu datasets (N = 1231), eight mutation carriers
were identified, and among the 526 ovarian cancer patients
from Helsinki, two mutation carriers were identified
(Table 1).
We evaluated the breast cancer risk among all geno-
typed patients (all BC) in each dataset separately (Table 1).
Furthermore, genotyped patients were divided into sub-
groups according to family history of cancer, ER status,
and triple-negative subtype to study the risks by breast
cancer phenotypes.
Breast cancer risk was increased among all breast cancer
patients in the Helsinki (OR 2.11, 95% CI 0.59–7.49,
P = 0.24), Tampere (OR 6.14, 95% CI 0.72–52.70,
P = 0.10), and Oulu datasets (OR 1.16, 95% CI 0.31–4.30,
P = 1), albeit with no statistically significant P-values. In
the Kuopio dataset, only two mutations carriers were
identified (OR 0.73, 95% CI 0.07–8.15, P = 1) (Table 1).
No significant heterogeneity was seen between the studies
(P = 0.9).
However, the FANCM c.5791C[T mutation associated
significantly with TNBC in the Helsinki dataset (OR 9.09,
95% CI 1.82–45.49, P = 0.02). In the Tampere and Oulu
datasets, two additional triple-negative cases were
identified.
The analysis of ovarian cancer cases from the Helsinki
dataset suggested possibly slightly increased risk among
c.5791C[T carriers (OR 1.60, 95% CI 0.27–9.58,
P = 0.64, Table 1); however, there were only two muta-
tion carriers identified. One patient has serous ovarian
cancer, whereas the other mutation carrier has been diag-
nosed with mucinous subtype of the disease.
We further performed a combined analysis of the four
studies to evaluate the risk among all studied breast cancer
patients. An elevated breast cancer risk for the c.5791C[T
carriers was seen among all breast cancer patients (OR
1.94, 95% CI 0.87–4.32, P = 0.11), and particularly in the
TNBC subgroup (OR 5.14, 95% CI 1.65–16.0), with a
statistically significant P value (0.005) (Table 2).
In addition, the breast cancer risk was increased also in
the other subgroups, e.g., ER negative (OR 2.34, 95% CI
0.75–7.35, P = 0.14) and familial breast cancer (OR 2.50,
95% CI 0.83–7.51, P = 0.10) (Table 2), but the results did
not reach statistical significance.
Combined analyses of the FANCM c.5791C>T
and c.5101C>T mutations
We combined the results from the current analyses of the
FANCM c.5791C[T mutation with the previous risk study
of the FANCM c.5101C[T mutation in the Helsinki and
Tampere datasets [12], and genotyping results from Oulu
and Kuopio cases and controls. Highly significant associ-
ation was seen between breast cancer and carrying either of
the mutations (OR 1.86, 95% CI 1.32–2.49, P = 0.0002).
The risk was consistently increased in all subgroups of
patients, with highest risk and the most significant associ-
ation seen among the triple-negative patients (OR 3.08,
95% CI 1.77–5.35, P = 0.00007) (Table 3). No hetero-
geneity was seen between mutations (P = 0.7). All anal-
yses were stratified by study.
Genotyping of the FANCM c.4025_4026delCT
and c.5293dupA variants
The FANCM c.5293dupA and c.4025_4026delCT variants
were genotyped among 862 familial breast cancer patients
from the Helsinki area. No additional mutation carriers
were identified for c.5293dupA variant which may repre-
sent a unique mutation in the family where it was
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identified. The mutation was originally identified in exome
sequencing of a uterine cancer patient with a family history
of breast cancer.
One additional carrier was identified for
c.4025_4026delCT, totaling two carriers for this rare
variant and was not studied further. The patients´ ages at
diagnosis were 42 and 54, respectively. One carrier had
ER-negative breast cancer, whereas the other had ER-
positive disease. Both had family history of breast cancer,
but no additional samples were available for genotyping
the relatives. The ExAC population frequency for the
c.4025_4026 deletion in Finland is 0.015%.
Discussion
In this current case–control study, we evaluated the breast
and ovarian cancer risk for the FANCM c.5791C[T
mutation as well as for c.4025_4026delCT and c.5293dupA
variants among Finnish population. We further examined
Table 1 Frequency of the
FANCM c.5791C[T mutation
in the studied sample sets by
breast cancer subgroups and in
the population controls
Study cohort N CC (%) CT (%) OR 95% CI P value
Helsinki
Controls 1258 1255 (99.8) 3 (0.2) – – –
All BC 2391 2379 (99.5) 12 (0.5) 2.11 0.59–7.49 0.24
Unselected BC 1699 1690 (99.5) 9 (0.5) 2.23 0.60–8.25 0.22
Familial BC 1078 1073 (99.5) 5 (0.5) 1.95 0.46–8.18 0.48
C3 affected 523 520 (99.4) 3 (0.6) 2.41 0.49–12.00 0.37
2 affected 555 553 (99.6) 2 (0.4) 1.51 0.25–9.08 0.64
ER? 1795 1786 (99.5) 9 (0.5) 2.11 0.57–7.80 0.25
ER- 412 409 (99.3) 3 (0.7) 3.07 0.62–15.26 0.16
TNBC 141 138 (97.9) 3 (2.1) 9.09 1.82–45.49 0.02
Unselected OC 526 524 (99.6) 2 (0.4) 1.60 0.27–9.58 0.64
Tampere
Controls 808 807 (99.9) 1 (0.1) – – –
All BC 662 657 (99.2) 5 (0.8) 6.14 0.72–52.70 0.10
ER? 494 490 (99.2) 4 (0.8) 6.59 0.73–59.11 0.07
ER- 122 121 (99.2) 1 (0.8) 6.67 0.41–107.34 0.25
TNBC 68 67 (98.5) 1 (1.5) 12.04 0.74–194.74 0.15
Oulu
Controls 510 507 (99.4) 3 (0.6) – – –
All BC 1323 1314 (99.3) 9 (0.7) 1.16 0.31–4.30 1
Unselected 1147 1141 (99.5) 6 (0.5) 0.89 0.22–3.57 0.87
Familial BC 153 150 (98.0) 3 (2) 3.38 0.68–16.92 0.14
YBR 56 56 (100) 0 (0) – – –
ER? 434 432 (99.5) 2 (0.5) 0.78 0.13–4.70 1
ER- 109 108 (99.1) 1 (0.9) 1.56 0.16–15.19 0.54
TNBC 69 68 (98.6) 1 (1.4) 2.49 0.25–24.23 0.40
Kuopio
Controls 158 157 (99.4) 1 (0.6) – – –
All BC 430 428 (99.5) 2 (0.5) 0.73 0.07–8.15 1
ER? 318 317 (99.7) 1 (0.3) 0.50 0.03–7.97 1
ER- 95 95 (100) 0 (0) – – –
TNBC 47 47 (100) 0 (0) – – –
All BC: all genotyped breast cancer cases in designated study. C3 affected: families with three or more
breast or ovarian cancer cases among first- or second-degree relatives. 2 affected: families with two first-
degree relatives with breast or ovarian cancer
The patient subgroups are overlapping with 386 familial cases belonging also to the unselected cohort in the
Helsinki data set and 33 familial cases belonging to the unselected cohort in Oulu data set. The patients may
also belong to different subgroups by tumor phenotype
BC breast cancer, OC ovarian cancer, ER estrogen receptor, TNBC triple-negative breast cancer, YBR young
breast cancer patients (age at diagnosis B40 years) among Oulu data set
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the risk associated with carrying either of the FANCM
mutations c.5101C[T and c.5791C[T.
The study revealed the FANCM c.5791C[T mutation
being more frequent among the studied breast cancer cases
than in controls in the Finnish population. It was particu-
larly enriched among the TNBC cases, showing a signifi-
cant association in the combined analysis (OR 5.14,
P = 0.005). This observation is consistent with previous
studies on FANCM and breast cancer risk, as the
c.5101C[T mutation has also been found to associate with
TNBC [12, 14]. Consistent results were seen also in the
other subgroups studied (Table 2).
We further combined the results of the FANCM
c.5101C[T risk analysis [12] with the current results of
c.5791C[T to study the risk associated with carrying either
of these C-terminal FANCM mutations. The risk was sig-
nificantly increased in all subgroups of patients, especially
among triple-negative cases (OR 3.08, 95% CI 1.77–5.35,
P = 0.00007).
Studying the c.5791C[T mutation in the ovarian cancer
cases showed an elevated risk (OR 1.60), but the
association was not statistically significant. Previous stud-
ies on FANCM mutations have shown similar results
[12, 14]; however, a very recent study found significant
association between FANCM mutations and high grade
serous ovarian cancer [36].
Screening of the other two FANCM variants exposed
only one additional c.4025_4026delCT carrier and no
c.5293dupA carriers among 862 familial breast cancer
patients, and these were not studied further. However, their
identification may suggest a wider mutation spectrum of
very rare mutations in the FANCM gene, potentially
relating to subtype-specific breast cancer predisposition.
Of all breast cancers, about 10–20% are found to be
hormonally triple-negative and these are usually aggressive
with a poor prognosis, as this subtype does not respond to
hormonal therapy. These tumors are often higher grade and
larger size than the other tumor subtypes [37]. Germline
mutations in BRCA1 are common in TNBC cases, but
deleterious changes in other homologous recombination
DNA repair pathway genes have also been observed to
occur relatively frequently in these patients, including
Table 2 Combined analysis including all the sample sets (Helsinki, Tampere, Kuopio, and Oulu) in different subgroups, with number of the
c.5791C[T mutation carriers and non-carriers
Study cohort OR P 95% CI N Helsinki wt/mut N Tampere wt/mut N Oulu wt/mut N Kuopio wt/mut
All BC 1.94 0.11 0.87–4.32 2379/12 657/5 1314/9 428/2
Familial BC 2.50 0.10 0.83–7.51 1073/5 – 150/3 –
Unselected BC 1.87 0.14 0.82–4.26 1690/9 657/5 1141/6 428/2
ER? 1.86 0.16 0.78–4.41 1786/9 490/4 432/2 317/1
ER- 2.34 0.14 0.75–7.35 409/3 121/1 108/1 95/0
TNBC 5.14 0.005 1.65–16.0 138/3 67/1 68/1 47/0
BC breast cancer, ER estrogen receptor, TNBC triple-negative breast cancer, wt wild type, mut mutation carrier
Table 3 Combined analysis including all the sample sets (Helsinki, Tampere, Kuopio, and Oulu) in different subgroups, with the number of the
FANCM c.5101C[T and c.5791C[T mutation carriers (combined) and non-carriers
Study
cohort
OR P 95% CI N
Helsinki
wt/mut
N
Tampere
wt/mut
N
Oulu
wt/mut
N
Kuopio
wt/mut
N Helsinki
controls
wt/mut
N Tampere
controls
wt/mut
N Oulu
controls
wt/mut
N Kuopio
controls
wt/mut
All BC 1.86 0.0002 1.32–2.49 2285/81 656/35 1293/
30
419/11 1234/21 782/21 498/12 157/1
Familial
BC
1.99 0.004 1.24–3.19 1020/38 – 148/5 – – – – –
Unselected
BC
1.77 0.0006 1.28–2.45 1652/58 656/35 1124/
23
419/11 – – – –
ER? 1.64 0.005 1.17–2.32 1721/55 480/22 426/8 292/8 – – – –
ER- 2.02 0.004 1.25–3.25 405/16 114/8 108/1 99/2 – – – –
TNBC 3.08 0.00007 1.77–5.35 130/10 60/5 68/1 58/2 – – – –
BC breast cancer, ER estrogen receptor, TNBC triple-negative breast cancer, wt wild type, mut mutation carrier
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BRCA2, PALB2, BARD1, and RAD51C [38]. The FA
pathway has also been connected to TNBC, as comparison
of mRNA expression in different breast tumor types
revealed several FA pathway genes (BRCA1, FANCD2,
FANCF, and PALB2) being significantly less expressed in
TNBC tumors compared to luminal A (ER or PR positive)
tumors [39]. This further supports the current finding that
also FANCM depletion is linked especially with TNBC,
but deeper understanding of this connection warrants fur-
ther investigations. However, as the developmental mech-
anisms of TNBC are not well known, the identification of
additional risk factors for this breast cancer subtype is
valuable for understanding its etiology and for the identi-
fication of potential therapeutic targets.
FANCM has a crucial function in the DNA damage
response for ICLs. It acts as a helicase/translocase and
binds adjacent to the crosslink, inducing the recruitment of
the FA core complex to the site. The core complex
monoubiquitinates the FANCI–FANCD2 complex which
triggers the accumulation of multiple nucleases and initi-
ates the actual DNA repair processes [2]. Depletion of
FANCM has been reported to have effects on both the FA
pathway efficiency and tumorigenesis: FANCM deficient
mouse embryonic fibroblasts displayed increased chromo-
somal breakage, residual FANCD2 monoubiquitination,
and increased spontaneous sister chromatid exchanges, and
the FANCM knockout mice had reduced overall and
tumor-free survival [40].
The functional effect of FANCM c.5791C[T has pre-
viously been studied by Peterlongo et al. [13]. Instead of
being a conventional nonsense mutation, it was proposed to
create a binding site for a splicing factor hnRNP A1, which
causes exon 22 skipping in mRNA and introduces a pre-
mature stop codon, leading to loss of 132 amino acids from
the C-terminus of the protein. Two domains with important
roles in binding of DNA, ERCC4 and helix–hairpin–helix
(HhH)2, are located in the C-terminus of FANCM [41], and
loss of them likely disturbs FANCM activity. Supporting
this hypothesis, when the FANCM c.5791C[T mutation
was introduced to mouse embryonic fibroblasts, the mutant
cells displayed decreased DNA repair activity and
increased chromosomal breakage [13]. This is consistent
with the effect of the majority of the known breast cancer-
associated gene mutations [42], further supporting the
impact of FANCM c.5791C[T on genomic instability and
increased cancer risk.
Altogether, the c.5791C[T mutation has to date been
connected to familial breast cancer [13], and also to TNBC
[14]. The current results on FANCM c.5791C[T, together
with those of c.5101C[T, support a role for FANCM as a
moderate-risk breast cancer susceptibility gene and further
emphasize its connection with the triple-negative breast
tumors.
Conclusions
The current results provide further support for the previ-
ously suggested association between FANCM mutations
and triple-negative breast cancer. Further studies with lar-
ger datasets are needed for precise risk estimations. Also,
other rare variants may occur in the FANCM gene and
warrant further investigations in other populations.
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